Cedric Francois, Apellis CEO (Optum via YouTube)
June 30, 2021 04:15 PM EDT
Deals
Cell/Gene Tx

Apel­lis, Beam team up to test base edit­ing against the broad field of com­ple­ment dis­or­ders

Jason Mast

Editor

Last sum­mer, as Apel­lis was prepar­ing for the ap­proval of its po­ten­tial block­buster PNH drug Em­paveli, CEO Cedric Fran­cois sat down with his team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times